{"id":"W4391166174","doi":"10.1016/s1474-4422(23)00454-4","title":"Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":33,"is_retracted":false,"has_abstract":false,"ca_institutions":"iCo Therapeutics (Canada); University of British Columbia","funders":"Wellcome Trust; Active Biotech; European Huntington's Disease Network; Teva Pharmaceutical Industries","keywords":"Huntington's disease; Medicine; Placebo; Clinical endpoint; Internal medicine; Adverse effect; Physical therapy; Clinical trial; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002566663,0.002284173,0.003463169,0.0005389407,0.0005570645,0.001224012,0.001300648,0.003322322,0.005197853],"category_scores_gemma":[0.001960326,0.0009180051,0.001755866,0.0003430142,0.001889236,0.001689184,0.0004802009,0.002875536,0.001053633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008690751,"about_ca_system_score_gemma":0.00100134,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008163362,"about_ca_topic_score_gemma":0.001605777,"domain_scores_codex":[0.9991559,0.0004434507,0.00004538874,0.0001634999,0.00006560989,0.0001261197],"domain_scores_gemma":[0.9989499,0.0002956555,0.0002123037,0.0001013988,0.00009014711,0.0003505335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9786705,0.006147652,0.0004175554,0.0004286245,0.0006163355,0.0000406997,0.00005127257,0.0001487455,0.004661776,0.00006603323,0.0005372154,0.008213522],"study_design_scores_gemma":[0.9348567,0.06276647,0.00137943,0.00001604539,0.0002208236,0.00002024491,0.00001263393,0.0001175946,0.0002490904,0.00006479478,0.000282968,0.00001333726],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884508,0.004638456,0.0008013229,0.0005393086,0.0004729118,0.002660468,0.0009616893,0.0001313509,0.001343802],"genre_scores_gemma":[0.9872527,0.00215571,0.001558619,0.00145489,0.0006297292,0.003148006,0.001181289,0.00003889913,0.002580069],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005197853,"threshold_uncertainty_score":0.01738852,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04614417203517779,"score_gpt":0.3386271924069397,"score_spread":0.2924830203717619,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}